Drug Profile
Fluocinolone acetonide - Alimera/EyePoint Pharmaceuticals
Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal implant; Fluocinolone acetonide intravitreal insert; Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals; Iluvien; Injectable micro-insert - Alimera Sciences/EyePoint Pharmaceuticals; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/EyePoint Pharmaceuticals; OT-401; OT-703; YUTIQ; YUTIQ50Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator pSivida Inc
- Developer Alimera Sciences; EyePoint Pharmaceuticals; Horus Pharma; Hospital for Special Surgery; Johns Hopkins University; Ocumension Therapeutics; pSivida Inc; Specialised Therapeutics Australia
- Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
- Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetic macular oedema; Uveitis
- Phase II Retinal vascular occlusion; Wet age-related macular degeneration
- No development reported Osteoarthritis
Most Recent Events
- 08 Feb 2024 NICE issues final draft guidance recommending fluocinolone acetonide for Diabetic macular edema
- 08 Sep 2023 EyePoint Pharmaceuticals terminates a phase III trial in Uveitis (Treatment-experienced) in USA (Intravitreous) (NCT05070728)
- 18 May 2023 Fluocinolone acetonide licensed to Alimera Sciences outside of China, Hong Kong, Taiwan, Macau and Southeast Asia for eye disorders